Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


English prescription charges become political target

This article was originally published in Scrip

Executive Summary

The UK's governing Labour party is proposing to use savings from the national drugs budget to eliminate the prescription charges that some patients pay for medicines. Gordon Brown, the prime minister, told a party conference that cancer patients would no longer pay such charges from next year, currently £7.10 per prescription or £102.50 annually. "As over the next few years the national health service generates cash savings in its drugs budget we will plough savings back into abolishing charges for all patients with long-term conditions," he added. His plan would apply only to the NHS in England; the Welsh regional government has already abolished prescription charges and the Scottish Executive is phasing them out. Old people and others receiving social assistance in England are already exempted from paying the charges. The Labour party is much weaker than the Conservative opposition in opinion polls, but an election is not required until 2010.

You may also be interested in...

Cervarix link to UK girl's death "unlikely"

Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.

Generic Topamax launched in European markets

Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.

NICE confirms limits on Alimta for lung cancer

Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts